Summary
Cencora, Inc. (COR) reported a significant year-over-year decline in net income for the three months ended June 30, 2017, primarily due to a substantial increase in litigation settlement charges. Revenue showed modest growth of 4.9% for the quarter, driven by increased sales within its Pharmaceutical Distribution Services segment, particularly from larger customers and ABSG business units, though this was partially offset by a decline in sales of Hepatitis C products. The company's balance sheet reflects a strong increase in accounts receivable and merchandise inventories, alongside a significant decrease in cash and cash equivalents compared to the prior year-end. While the company maintains substantial liquidity through its revolving credit facilities, the operating cash flow for the first nine months of fiscal 2017 was notably lower than the previous year, impacted by changes in payment terms with a major customer and a significant litigation settlement payment expected before the fiscal year-end. Investors should closely monitor the resolution of ongoing legal matters and their potential impact on future financial performance.
Financial Highlights
54 data points| Revenue | $38.71B |
| Cost of Revenue | $37.63B |
| Gross Profit | $1.08B |
| SG&A Expenses | $525.46M |
| Operating Income | $170.38M |
| Net Income | $50.35M |
| EPS (Basic) | $0.23 |
| EPS (Diluted) | $0.23 |
| Shares Outstanding (Basic) | 218.68M |
| Shares Outstanding (Diluted) | 221.87M |
Key Highlights
- 1Revenue increased by 4.9% to $38.7 billion for the quarter ended June 30, 2017, compared to the prior year, driven by growth in Pharmaceutical Distribution Services and other segments, despite a decline in Hepatitis C product sales.
- 2Net income for the quarter significantly decreased to $50.4 million from $349.2 million in the prior year, largely due to $273.4 million in litigation settlements and related charges recorded in the current period.
- 3Operating income for the quarter saw a substantial decline of 68.1% to $170.4 million from $528.6 million in the prior year, heavily influenced by increased litigation expenses.
- 4Accounts receivable increased by $1.37 billion and merchandise inventories by $945.6 million compared to the prior year-end, contributing to a decrease in cash and cash equivalents from $2.74 billion to $1.31 billion.
- 5Cash provided by operating activities for the nine months ended June 30, 2017, decreased significantly to $123.7 million from $1.82 billion in the prior year, impacted by changes in working capital, including increased receivables and inventories, and a large customer payment term adjustment.
- 6The company recorded significant charges for litigation settlements, totaling $273.4 million for the quarter and $289.4 million for the nine months ended June 30, 2017, including a $260 million agreement in principle with the U.S. Attorney's Office for the Eastern District of New York.
- 7The company has a robust debt structure with substantial availability under its revolving credit facilities and receivables securitization facility, indicating strong liquidity despite reduced cash on hand.